Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 6

Treatment Choices for Recurrent dMMR Endometrial Cancer

,

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
Now Viewing
EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer